📰 Morphic Holding News
Page 9 - Morphic Holding News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Morphic Holding. Real-time updates on events, politics, business and more.
April 18, 2023
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 10,063 put options on the company. This represents an increase of 2,987% compared to the typical daily volume of 326 put options. Insider Activity at Morphic In related news, President Bruce Rogers sold 10,000 shares […]
April 9, 2023
MetLife Investment Management LLC lowered its stake in Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,185 shares of the company’s stock after selling 1,597 shares during the quarter. MetLife Investment […]
April 9, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally speaking, biotech stocks to buy offer investors an excellent opportun...
March 23, 2023
Shares of Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) fell 5% on Thursday . The stock traded as low as $36.28 and last traded at $36.54. 266,512 shares were traded during trading, a decline of 27% from the average session volume of 366,663 shares. The stock had previously closed at $38.47. Analyst Ratings Changes Several […]
March 23, 2023
Should You Buy or Sell Morphic Stock? Get The Latest MORF Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
December 15, 2022
The biotech sector has shown signs of recovery in recent months, driven in part by favourable commercial performance and clinical readouts, according to RBC...
December 14, 2022
The biotech sector has shown signs of recovery in recent months, driven in part by favourable commercial performance and clinical readouts, according to RBC...
August 3, 2022
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in... | August 3, 2022
May 20, 2022
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) has earned an average rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that […]
March 4, 2022
WALTHAM, Mass., March 04, 2022 -- Morphic Therapeutic , a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today... | March 4, 2022